18
ALL18
Journey Medical CorporationYear
18
ALL3
20247
20235
20223
2021DEALS // DEV.
18
ALL6
Deals12
DevelopmentsCountry
18
ALL18
U.S.A18
ALL7
Dr. Reddy's Laboratories1
Eli Lilly1
Maruho6
Not Applicable1
SWK Holdings1
Undisclosed1
VYNE TherapeuticsTherapeutic Area
18
ALL18
DermatologyStudy Phase
18
ALL5
Approved13
Phase IIIDeal Type
6
ALL1
Acquisition1
Agreement1
Collaboration1
Divestment1
Financing1
PartnershipProduct Type
18
ALL18
Small moleculeDosage Form
17
ALL1
Capsule6
Capsule, Extended Release7
Modified Release Capsule1
Topical Foam2
WipesLead Product
18
ALL2
Glycopyrronium Tosylate1
Isotretinoin15
Minocycline HydrochlorideTarget
3
ALL2
M3 receptor1
RARLead Product(s) : Minocycline Hydrochloride
Therapeutic Area : Dermatology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Journey Medical Announces FDA Approval of Emrosi™ for Rosacea
Details : FDA has approved Emrosi (minocycline hydrochloride extended release capsules), formerly referred to as DFD-29, for the treatment of inflammatory lesions of rosacea in adults.
Product Name : Emrosi
Product Type : Small molecule
Upfront Cash : Not Applicable
November 04, 2024
Lead Product(s) : Minocycline Hydrochloride
Therapeutic Area : Dermatology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Minocycline Hydrochloride
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Dr. Reddy\'s Laboratories
Deal Size : Not Applicable
Deal Type : Not Applicable
Journey Medical Announces FDA Acceptance Of DFD-29 for Rosacea Treatment
Details : DFD-29 (minocycline hydrochloride) has anti-inflammatory properties independent of antibacterial activity. It is being evaluated for treating papulopustular rosacea.
Product Name : DFD-29
Product Type : Small molecule
Upfront Cash : Not Applicable
March 18, 2024
Lead Product(s) : Minocycline Hydrochloride
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Dr. Reddy\'s Laboratories
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Minocycline Hydrochloride
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : SWK Holdings
Deal Size : Undisclosed
Deal Type : Financing
Journey Medical Secures Up to $20 Million Credit Facility with SWK Holdings
Details : The funding will support anticipated expenses for DFD-29 (minocycline hydrochloride), developed for treating rosacea, including an upcoming NDA submission and preparation for its potential launch.
Product Name : DFD-29
Product Type : Small molecule
Upfront Cash : Undisclosed
January 02, 2024
Lead Product(s) : Minocycline Hydrochloride
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : SWK Holdings
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Minocycline Hydrochloride
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Dr. Reddy\'s Laboratories
Deal Size : Not Applicable
Deal Type : Not Applicable
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea
Details : DFD-29 (minocycline hydrochloride) has anti-inflammatory properties independent of their antibacterial activity that correlate with certain aspects of the pathophysiology. It is being evaluated in phase 3 trials for the treatment of papulopustular rosace...
Product Name : DFD-29
Product Type : Small molecule
Upfront Cash : Not Applicable
December 05, 2023
Lead Product(s) : Minocycline Hydrochloride
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Dr. Reddy\'s Laboratories
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Minocycline Hydrochloride
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : DFD-29 (minocycline hydrochloride modified release capsules) has anti-inflammatory properties independent of their antibacterial activity that correlate with certain aspects of the pathophysiology. It is currently being investigated for the treatment of ...
Product Name : DFD-29
Product Type : Small molecule
Upfront Cash : Not Applicable
October 20, 2023
Lead Product(s) : Minocycline Hydrochloride
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Minocycline Hydrochloride
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : DFD-29 (minocycline hydrochloride modified release capsules) was developed using Multiple Unit Pellet System technology, which is being investigated for the treatment of papulopustular rosacea.
Product Name : DFD-29
Product Type : Small molecule
Upfront Cash : Not Applicable
July 11, 2023
Lead Product(s) : Minocycline Hydrochloride
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Minocycline Hydrochloride
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Dr. Reddy\'s Laboratories
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : DFD-29 (minocycline hydrochloride modified release capsules) was developed using Multiple Unit Pellet System technology, which is being investigated for the treatment of papulopustular rosacea.
Product Name : DFD-29
Product Type : Small molecule
Upfront Cash : Not Applicable
July 03, 2023
Lead Product(s) : Minocycline Hydrochloride
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Dr. Reddy\'s Laboratories
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Minocycline Hydrochloride
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Dr. Reddy\'s Laboratories
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : DFD-29 (minocycline hydrochloride modified release capsules) was developed using Multiple Unit Pellet System technology, which is being investigated for the treatment of papulopustular rosacea.
Product Name : DFD-29
Product Type : Small molecule
Upfront Cash : Not Applicable
June 13, 2023
Lead Product(s) : Minocycline Hydrochloride
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Dr. Reddy\'s Laboratories
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Minocycline Hydrochloride
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : DFD-29 (minocycline) has anti-inflammatory properties independent of their antibacterial activity that correlate with certain aspects of the pathophysiology. It is currently being investigated for the treatment of papulopustular rosacea.
Product Name : DFD-29
Product Type : Small molecule
Upfront Cash : Not Applicable
March 16, 2023
Lead Product(s) : Minocycline Hydrochloride
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Minocycline Hydrochloride
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : DFD-29 (minocycline) has anti-inflammatory properties independent of their antibacterial activity that correlate with certain aspects of the pathophysiology. It is currently being investigated for the treatment of papulopustular rosacea.
Product Name : DFD-29
Product Type : Small molecule
Upfront Cash : Not Applicable
January 10, 2023
Lead Product(s) : Minocycline Hydrochloride
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable